Wenr Corp (WNRC): New Cable TV Player Scoring BIG While Trading Under The Radar.

Big things are happening for a small company in the Cable TV business. Just months ago, Wenr Corp (WNRC) was a non-operating pink sheets company with 38 million shares outstanding and a tiny public float of only 13.8 million shares. As a non-op, shares sold at a penny. Today, the share structure hasn’t changed, but the share price is in the mid-teens — the few (so far) who are watching closely, think it has much higher to go.

So what happened with this little pinkie that got investors so excited? Quite a bit, as it turns out. Let’s begin with the purchase of two TV station licenses in a bankruptcy court fire sale for a combined $45,000. The company has created a mini media-empire that many of the bigger players could look to for lessons in inspired deal-making.

With his bargain-priced licenses in hand, company Chairman Dan Green hired and called on Manny Martinez, the Charter Communications Vice President and General Manager for California and Nevada, to turn these licenses into revenue.

As Martinez well knows, after a long career in the cable business, building an entirely new TV station is an incredibly expensive proposition. Martinez proposed a better alternative. Through his guidance, WNRC quickly became the Reno affiliate for both the Azteca America and Mexicanal TV Networks. These are two of the largest and fastest growing Spanish language networks in the US, serving Reno’s Latino demographic of 30%.

WNRC receives the benefit of retransmitting a ready-made day program: Azteca and Mexicanal pay WNRC monthly carriage fees merely for retransmitting their network signals. Besides circumventing the financial strain in having to build a new television network, WNRC has also enter the world of high-margin ad-selling.

Elsewhere the company has begun to lay groundwork for a Small Cap Financial Network that they anticipate launching locally, in the Nevada market, with the intention of expanding nationwide with the help of various national cable providers. The possibility of some future press release announcing nationwide rollout of the new financial network is simply mind-blowing.
 
Not a bad few months work for this duo, but even still they were far from done. How about picking up ownership interests in a couple of radio stations? You know, the kind that are networked nationally like the TV networks WNRC works with – simply retransmitting the national feed and getting right to the meat and potatoes of selling advertising and generating revenue? That is just what they did – first with a popular Latino music station and now with the only jazz station in Reno.

There’s more.

The rigid economy has forced larger cable providers to take a hard look at their operations and cut costs anywhere they can. Several of them came to the conclusion that carrying cable subscribers in outlying, sparsely populated regions are, while still highly profitable, an overhead burden they’d rather do without. Who better to sell them to than a company like WNRC? The company has already acquired a few thousand cable subscribers…and is in non-disclose negotiations for the purchase of several thousand others. Industry-wide, these subscribers are typically valued at $4000 per household. The only thing that makes this even more exciting is that the acquisitions are financed through seller-financing. That’s no joke. And as it turns out, if your team includes a cable industry heavyweight like Martinez, the large companies will finance the sale of smaller 5000 to 20,000 systems.

Green has found the shortcut to revenue and cash flow. Period. He has repeatedly “bypassed” the messy, difficult and expensive work of having to build from scratch and positioned WNRC as the revenue “gatekeeper”. Oh yes, it’s quite remarkable. 

But I saved the best part for last. This guy, Dan Green, has really “got it”. Revenue, Cash Flow, Profitability and Share Structure are what it’s all about. No dilution or big cash outlays for him. In fact, he financed the company with personal funds until it became self-sustaining. Martinez, on his part, is a seasoned pro. He’s always on the prowl for shrewd deals where he’s recognized and respected enough to earn top spot in negotiations.

The relatively few investors who have caught on to what WNRC has accomplished so far, and the cable industry veterans who understand the realignment taking place with smaller outlying cable systems have to wonder just how long this can remain an undiscovered gem.

Article courtesy of a WNRC Shareholder

A Technical Approach to the Trading Week Ahead

I often find portfolio managers and investors describing themselves as top-down strategists. They look for trends at the macro level and apply their findings to individual trades. Spare me the humiliation of having skipped past rigorous scans that lie between the trends and the trading positions themselves, for I’m genuinely curious how these individuals prepare for an upcoming week. In lieu of my own curiosity I thought I’d offer an account of how I prepare for the week that lies ahead using technical analysis. Ah, now there’s something new.
 
Looking for trends at the macro level translates into an analysis of a leading index, such as the Dow Jones Industrial (DJI). I find stocks model the Dow fairly consistently whilst allowing me to deduce simple but potentially profitable trends. Here’s a look at the Dow Jones ahead of Monday’s session, through my eyes.
 
 

 
The Dow Weekly chart points to the formation of a bearish chart pattern termed ‘rising wedge’. Simultaneously volume is seen declining in combination with rising price. This is called negative divergence. Both of these technical indicators warn of an impeding correction. It does not imply that we are headed for absolute chaos or destruction, but rather, that the markets will ‘pull-back’. This lends way for some specific trading ideas. You might, for instance, knowing that the Dow trades downwards this week, short financial stocks. On the other hand you might use this knowledge to leverage your position in a bull or bear ETF, such as FAS or FAZ. But many will look to hedge with gold. Below is a look at SPDR Gold Shares (GLD) from a technical perspective.
 
 

 
Conversely to the Dow, gold is currently trading at support and in the midst of a bullish rising wedge chart pattern (assuming support remains intact). Depending on the severity of a pull-back in the equity market, gold may find itself once again testing resistance and potentially breaking out to new all-time highs. So I’m inclined to believe that gold stocks may benefit from this trend.
 
But where does that leave other stocks? As far as I’m concerned as a technical trader, that depends on the severity of movement to either the downside or the upside in the equity market. A look at the economic calendar reveals that a significant portion of data isn’t due until the latter part of this week. That tells me its unlikely that we will see a breakout, breakdown or significant movement until at least mid-week. This plays a crucial role, as I explain to my Premium subscribers, as it determines how you position yourself in trades that you’ve deemed appropriate based on earlier analysis (above).
 
It means there’s room to speculate with some other trades while your core positions mature. Similarly this period allows you to build your positions. At the end of the day you look back at your initial choices and compare to the current situation. Ask yourself what has changed, why, and how you can adjust to better position yourself for optimum reward.
 
In part, that’s what a technical approach to the trading week ahead may look like…at least it does for yours truly.

11 Reasons Why Apple (NASDAQ: AAPL) Could Fall in 2011

AAPL LogoAfter revolutionizing the technology of media and personal electronic devices for the 21st century, staging one of the greatest comebacks of any company in history, and dominating consumer and investor attention for the past five years, Apple (AAPL) may be setting up for a hard fall.

Down and almost out, Apple was nothing to be too excited about 10 years ago. Its Macintosh computers were the bulk of its product line, and PCs were in almost full control of the market. But with the invention of the iPod, which revolutionized the way we listen to and buy music, Apple began its road to recovery – which eventually led it not only to recovery, but to domination as well.
It’s hard to even imagine what things were like before the iPod. Walkmen, CD players and far-inferior MP3 players would be almost embarrassing nowadays in comparison to the iPod, which has become the icon for music devices in the past few years. And the addition of the iPhone to Apple’s product line was met with almost hysterical excitement, as lines outside of Apple stores became a common occurrence. Add to that a consistently-innovated computer and laptop line, thousands of “Apps” for the iPhone that allow people to do anything from looking up restaurants to turning on their cars, and the seemingly never-ending hype as to what Apple will do next, and it is obvious why Apple has been able to build such a powerhouse out of its brand.
But as is the case with every company, story, and fixation, the party eventually ends. Things can’t improve and improve and improve and improve forever. At some point, what was once popular becomes second-class; what was once innovative, becomes old-fashioned; what was once a well-kept secret becomes a monotonous, repetitive idea that offers no benefit.
What I’m saying is that at some point Apple will no longer sit as loftily as it now does. It could fail to innovate, fail to care for its customers, or simply fail to meet expectations. And when that happens, we can expect “Apple lovers” to snap out of their whole-hearted faithful love-affair, wreaking havoc on the stock price if not also sending the company into frenzy. There is no doubt that Apple is one of the greatest companies in the world, with some of the greatest consumer products and revolutionary technologies. But at what point does the fun end?
 
11 Reasons Why Apple Could Fall in 2011

1) Price Run-Up. Less than eight years ago, you could have bought Apple shares for $7. Today they’re sitting at an all-time high above $325 – more than a 4,600% gain!
Take a look at the following chart:

As you can see, there were plenty of opportunities to buy Apple if you missed the first moves: early 2006, early 2008, late 2008-early 2009, and basically at any point before today. The stock did not move straight up without pause; it offered investors numerous chances to jump in.

But after a 4,600% move, now sitting at all-time highs, and especially after such a steep rise since early 2009 – is there really that much room left to go? Aside from the fact that there are probably plenty of other investment opportunities that will outperform Apple, could such a meteoric rise in stock price continue for that much longer?
 
2) Market Cap. With a market cap of over $298 billion, Apple is now the second-largest company in the world. It recently became the world’s largest technology company, moving past Microsoft (MSFT), which was once in a similar position that Apple finds itself now. Besides for the fact that Apple is by no means the market-share leader in computers or phones, there is one much bigger point that just stands out in my mind. The market cap of Apple is equal to the market caps of IBM (IBM), Hewlett Packard (HPQ) and Dell (DELL) combined!
Moreover, it is hard to argue with the claim that it is much harder for a large company to grow as quickly as it did leading up to that point. In other words, as hard as it is to double a company’s market cap from $50 million to $100 million or from $10 billion to $20 billion, it is exponentially harder to take a huge company like Apple and grow its market cap from $300 billion to even $400 billion. Large corporations are sometimes like large, heavy objects much harder to move.

3)
CEO Steve Jobs. Undoubtedly the most prominent figure in Apple, if not the entire technology space, Steve Jobs has been the mastermind and visionary behind much of the company’s success. Yet while Jobs should be granted the utmost credit for his achievements, two issues could still derail the company.
First, his health is of major concern to the future of Apple. In 2004, Jobs announced that he had been diagnosed with pancreatic cancer. His health has been repeatedly scrutinized over the past few years, with Bloomberg even mistakenly publishing a 2,500-word obituary of Jobs in 2008. In April 2009, Jobs underwent a liver transplant, further pointing to the heightened issue of his health.
What happens if Steve Jobs is no longer able to lead Apple? The man who has been behind Apple’s revival and surge to the top of the technology world is seen by many to be vital to Apple’s continued success. Yes, he has established a very strong foundation on which the company can continue to build. But the loss of his vision and continued leadership will hurt the company in the short-term if not put a major damper on its growth in the long-term. Even if strong leadership is available to replace him, you can surely bet that many stockholders would be selling their shares if anything were to happen to him.
The second issue, which has been the downfall of many powerful men and innovative companies, is Jobs’ arrogance. Jobs has downplayed Apple’s surpassing Microsoft in market cap, rejected Adobe’s (ADBE) Flash technology for use in his own company’s products, and bashed competitors like Research in Motion (RIMM) and Google (GOOG). His arrogance has obviously brought him the success he now enjoys, but some of the excessive and unnecessary arrogance he may be guilty of could prevent Apple from taking part in new ventures, new ideas and new partnerships, and could even make Apple a target. One of the most important rules of wisdom and success is being open to new opportunities and not thinking that nobody else can offer good ideas. We’ll see how this one plays out.

4)
Extreme Expectations. After shattering analyst estimates again and again, expectations for Apple are higher than ever. They just haven’t ceased to amaze almost everyone with their record numbers, continuous innovation, and growing grasp of market share. There simply is no company out there like Apple.
But after exceeding investors’ expectations time and time again, is Apple setting up for disappointment? With 47 out of 50 analysts covering Apple maintaining a “Buy” rating and the remaining 3 a “Hold” rating, it’s hard to say investors could be any more bullish than they already are. Almost no one dares to bet against or even speak poorly of Apple; analyst price projections are hovering in the $400+ dollar range; and with Apple touted as everyone’s favorite stock for years now, it could be that all the high growth, big expectations, and future opportunities are already priced in. What happens if Apple slips or even just fails to meet the sky-high expectations that have been set for it? It’s understandable that Apple will drop if it completely screws something up; but what if it just fails to exceed expectations? After exceeding expectations for years, investors’ won’t settle for just meeting expectations. If Apple can’t continue on its course for growth, and do so in tremendous fashion, it could begin to lose its luster. And if it loses its luster, you can bet that many of those invested in Apple will begin to pull their money out in search of better investment opportunities. Nobody remains a crowd favorite forever.

5)
Anyone Left to Buy? After dominating the headlines, media coverage, and the minds of investors for years, is there anyone left who hasn’t bought Apple yet? Almost every fund and institution is invested in Apple; your grandmother is probably invested in Apple. If it’s no longer a well-kept secret, is it really a great investment anymore? And is there anyone left to swear to it? With all the opportunities to invest in it, I find it hard to believe that there are that many people left to buy it. Anyone who has wanted to already has. And though there may be some investors who may get into it again or even for the first time, there is a higher chance that those who own it will sell it at $325 – the new investors would, in effect, be buying from those who have owned it for a while. Smart money will be selling to last-to-get-in investors.

6)
Declining Quality. Apple used to be known for its product quality and customer service, but lately it appears it has been cutting some corners. Understandably so, as Apple tries to grow rapidly and has to keep up with demand and strict time schedules, it sometimes comes across some issues, such as getting its products out on time. But at the same time, a company that grows so quickly sometimes can’t keep up with quality and customer service; it simply doesn’t have the time or resources.
And where did we see this happen? The iPhone was shipped out as soon as possible, and ended up having faulty antennas. To make matters worse, Apple refused to recall the phones and shipped out iPhone “bumpers” instead. Moreover, many iPhones are functioning poorly – just ask some of your friends who own one. iPods have been dying on people for years, for no apparent reason. I’ve even heard people complain about the laptops recently – something Apple has never had problems with. And now, the iPad has been made with a reflective surface, which makes it almost impossible to use in the sunlight – how can anyone take it to the beach or use it outdoors? The Kindle, on the other hand, is made with a non-reflective surface, and avoids these issues. Apple must address these issues and keep up with quality control, or it faces the threat of losing loyal customers.

7) Innovation?
Apple is where it is today because it was able to introduce revolutionary products and continuously innovate them. But after a few generations of iPods, iPhones and laptops, innovation is somewhat lacking. It’s just not that easy to continuously improve on an already-successful product. Take the iPod, for example: it started off as a music-only, black-and-white display device. Then came color, video, internal speakers, touch-screen, Internet, and many other features. But what else is really left? Much of the good features have been introduced already. Many have therefore claimed that the iPods, iPhones and computers are now part of Apple’s core product line – meaning they will continue to grow, but fairly steadily.
The iPad is supposedly Apple’s new focus. I will admit that it’s an interesting and probably useful gadget. But is it really as innovative as investors believe it to be? To an extent, it’s really just a big iPhone or small laptop. And it also cannibalizes some of the iPhone, iPod and laptop sales. Since it offers very similar features to Apple’s other products, there is not much benefit in owning the iPad if one owns the iPhone, iPod and laptop. The iPad may just have been the result of Apple’s dire need to innovate, but innovation may have plateaued.

8 ) Competition.
Apple has hogged the spotlight and much of the smartphone and tablet market. But as other companies see the benefits and opportunities in the space, they will begin to ramp up the competition. The Android and the Blackberry continue to be threats to Apple’s iPhone market share, with Android actually growing faster. The iPad’s relative success also has interested companies like Samsung (SSNLF.PK), HP and Research in Motion to introduce their own respective tablets. It’s only a matter of time before Apple loses its “first-to-enter” role and faces the reality of a market with increasing competition. Another sign of Apple’s struggles is its recent sale of iTunes gift cards for less than their face value. Best Buy (BBY) recently sold $50 iTunes gift cards for $40. A 25% sale seems pretty desperate; it tells me that even Apple doesn’t believe its prices are justified. Apple does have the ability to remain on top and offer the most appealing products, but it definitely won’t be easy as it has been until now. And that could easily send the stock price lower.

9)
Hacking and Viruses. Unlike PCs, Apple computers have been known to be very resistant to viruses. While PCs have been plagued by hackers, viruses and other similar issues, the Apple system has been relatively safe. But as Apple computers continue to sell at an increasing rate, viruses and new problems are more likely. And if Macs begin to wear down at a quicker rate, they could lose some sales. My strategy has been to buy three PCs for the price of one Mac. Apple computers are just too expensive to justify, in my opinion; I’d rather buy three PCs over the course of a few years for the same price I’d be paying for one Apple laptop. That way, if I get a virus on one computer, I can just buy a new one without worrying about all the money I’ve spent. Unless Apple can continue to protect itself from viruses and maybe lower its prices a bit, it may face some fierce challenges.

10)
Weight in S&P 500 and NASDAQ 100. As Apple shares continued to rise, they have carried the broader market and indices with them. Apple is second only to Exxon (XOM) in the S&P 500 in terms of weighting, and makes up over 20 percent of the NASDAQ 100 (QQQQ), equal to the weighting of Microsoft, Google, Oracle (ORCL), Cisco (CSCO), Intel (INTC), Amazon (AMZN), and Research in Motion combined.
That means that for every one percentage point that Apple gains or loses, its impact on the NASDAQ 100 equals much bigger moves in any other individual stocks or even an equal move in the 6 next-biggest companies. In other words, the market and the indices heavily depend on Apple to continue to carry them upward; if Apple begins to fall, it will drag the rest of the market along with it. And regardless of how the other companies are doing, if investors start seeing the market drop, they are prone to avoid the market. Also, Apple’s weighting in the index will be up for review if its weight reaches 24% of the index. If that does happen, Apple’s weighting will be reduced, which will in turn result in less broad-market ETF money being invested in Apple. Right now, money being invested in the NASDAQ 100 through the QQQQ is being allocated heavily to Apple; if Apple’s weighting is reduced from 20%+, however, less money will be allocated to it, which could result in a weakening stock price.
Apple’s heavy weighting in both the S&P 500 and NASDAQ 100 make it the benefactor of a large portion of ETF and broad-sector investments, as allocations are based on a stock’s respective weighting. But at the same time, Apple’s heavy weighting makes it susceptible to a big drop if investors pull out their index ETF or funds, or if Apple’s weighting is recalculated in the NASDAQ 100. The market’s tremendous dependency on Apple is something to take note of.

11)
Poor Use of Cash. With over $25 billion in cash on its balance sheet, Apple is not efficiently putting its money to work. With these massive cash levels, Apple could have paid a dividend to shareholders, buy back stock, or even buy a few companies with promising technology or services. Instead, Apple is not rewarding its investors and isn’t improving through acquisitions. Its idle cash may be due to the uncertainty about the market or simply due to Steve Jobs’ arrogance in thinking the company doesn’t need to acquire any smaller companies. Either way, however, Apple isn’t making the best use of its resources.
Apple has been on top for years now. It is the favorite of many funds, individual investors and the media. It has revolutionized the technology and culture of music, mobile phones and computers. And it is expected to continue to shock the world with its capabilities. But expectations may simply be too high. After a 4,600% parabolic rise in stock price, the involvement of almost every investor, extreme expectations as to Apple’s future, a CEO with health issues and potentially-blinding arrogance, a tremendous market cap which could prevent it from growing as quickly as it has, increasing competition, slowing innovation, and declining quality and customer service, Apple’s euphoric peak may be rapidly approaching. With an almost euphoric position in the business and investment world, it may just take a small slip or a failure to exceed expectations to send Apple stock tumbling, triggering a snowball effect that sends institutions and investors running for the exits.
There has been no proof yet of Apple stock price slipping, but it has been stuck near the $320 range since October. Such a sideways move could be a sign of distribution at the top – as smart investors sell their shares to newcomers. Unless Apple can shoot out of this range, it may be setting up for some trouble. The best move for investors would be to wait and see which way it moves, and maybe even take some profits; with all the issues we’ve discussed, there may be too much risk out there.

 

Article courtesy of Yoni Jacobs of Chart Prophet Capital

Aastrom Biosciences (NASDAQ: ASTM) Sparks New Uptrend

A bullish crossover of the MACD indicator suggests the beginning of a new uptrend for Aastrom Biosciences, Inc. (ASTM). On Tuesday volume jumped to nearly three times the 3-month average without any news from the company. Volume, often interpreted as the lifeblood of a chart, measures strength behind price movement in technical analysis. With the price breaking above its 50 day moving average line (blue), Tuesday’s share volume confirms the ‘technical breakout’ – a move through or above a significant level of resistance.
 
More specifically, Tuesday’s session lent way for shares to climb above not one, but two levels of notable resistance. The primary breakout occurred once the price broke channel resistance (pink). We made a note of that in real-time here. As mentioned, a break above the 50MA followed suit (the secondary breakout). Additionally the RSI indicator turned upwards and broke above the 50 mark, another indication of strength behind the price rally.

 
StemCells Inc. (STEM, +1.83%) and Cell Therapeutics, Inc. (CTIC, +2.36%) were among other stem-cell companies to gain in trading on Tuesday. This data leads me to believe that Aastrom Biosciences’ more-than-modest jump in stock price (+16.6%) was fueled by more than just momentum in the market. One source pointed to a newscast praising Aastrom Biosciences (ASTM) in saving the lives of two individuals using their stem cell remedies.
 
Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company’s autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use.
 
As of their last quarterly filing, Aastrom Biosciences had total cash of $14.47M. However, an offering closed on December 15th, 2010 revealed the company’s entitlement to an additional $20.5M. As the offering was chiefly responsible for the declining share price (then) it largely eliminates the risk of another offering diluting shareholder value now and in the near-term.

Xoma Ltd: Raw, Uncut, and Unrated

Last week XOMA’s (XOMA) stock price rose roughly 200% and 54.7M shares traded hands. Excitement brewed over the company’s multi-purpose drug, XOMA 052, which investors anticipate the company will release positive phase 2 results on early in the upcoming year. Conversely, I’m not so encouraged by all the hoopla.

It brings tears to my eyes knowing that some investors have been given a false sense of hope and security in light of the rising stock price. But don’t count on that union. Arena Pharmaceuticals (ARNA) rose in anticipation of a FDA approval of their weight-loss drug, Lorcaserin, in these past summer months. Then in September shares plummeted shedding all of the previous months’ gains in less than a week.

XOMA Ltd. (XOMA) has a reputation for misbehaving – which may explain why its Chief Executive was runner up to the least-distinguished biotech CEO of the year award. Elsewhere, XOMA has been called a “one-trick pony“. But more concerning is that both claims can be substantiated and then some. Last quarter, for instance, XOMA had total revenues of $10.9M versus $27.4M during the comparable period in 2009 (1). Concurrently, Operating expenses rose 33% year-over-year, mainly due to the rise in research and development costs. However, the troubling part is not that revenues have slid or that expenses have substantially risen or that operating activities alone burned through $43M in cash, but whom XOMA will turn to in order to finance ongoing operations.

XOMA Ltd. raised more than $40M selling paper to investors in the first three quarters of 2010. You can bet they’ll be at it again in the upcoming periods. Just earlier this year the company facilitated a 1-15 reverse stock-split after diluting their share price into the pennies. And now their future largely depends on a development-stage drug that will drain tens, if not hundreds, of millions of dollars from investors’ pockets before it is even given a chance at being commercialized.

In 20+ years of operations, XOMA Ltd. has incurred an accumulated deficit of more than $835M. Not one of those years did the company show a profit or so much as breakeven. If there is one trend that has remained consistent with Xoma Ltd. throughout their years, it’s been the careless expenditure of shareholder monies.

So I ask, what could have accounted for the discrepancy between the 21.78M shares floating and the 54.7M that actually traded hands? Was it a wave of heroic day traders or devilish short sellers? I think not. To quote Benjamin Graham, “watch out for OPM (Other Peoples’ Money) addicts”.

Lastly, on the topic of share capitalization, it puzzles me how a company with a supposed blockbuster drug can have so little vested interest on the part of those on the inside. According to Yahoo Finance, insiders hold just 2.56% of the total number of shares outstanding. But I’ll leave this issue at that.

On the basis of the daily chart, three technical indicators, RSI (95), MFI (99) and CCI (398), show the stock price to be overbought. Currently, the price is considered to be overextended to the upside or ‘overbought’ relative to the position of the upper bollinger band, an indicator of price deviation from the norm. This means that the price will likely pull back to at least par with the upper BB (currently at $5.10). Another significant supporting trendline is indicated on the chart (below).

XOMA Daily Chart

1. Financial Data Taken From Quarterly Filing (10Q)

Three Upcoming Make-or-Break Biotech Approvals

The lure of biotech has attracted droves of investors with stomachs for risk ever since the industry’s inception in the 1970s. Biotech investors continue to funnel money into fledgling enterprises–all the while enduring shareholder dilution, enormous uncertainty, and years of net losses–hoping to catch the next Amgen (AMGN) or Genentech.

The meteoric rise in the overnight share prices of modern-day Lazuruses like Vanda Pharmaceuticals (VNDA) and, most recently, Orexigen Therapeutics (OREX) have become the stuff of biotech legends. However, it is important to remember that many more biotechs crash and burn than make it big.

More often than not, biotech shareholders are left empty-handed. Below we highlight three development-stage biotechs with highly anticipated new therapies that are about to face judgment days of their own.

Vertex’s Telaprevir Aims to Revolutionize HCV Treatment

Vertex (VRTX) is close to commercializing its hepatitis C drug telaprevir, part of a new class of therapies that have the potential to revolutionize the way the disease is treated. HCV’s current standard of care requires 48 weeks of treatment, causes terrible side effects, and is still only able to cure patients 50% of the time. In contrast, telaprevir has the potential to cut treatment time in half and double cure rates. The drug is widely regarded as a major advancement, and we think telaprevir could hit the market in the first half of next year.

Vertex’s chief rival, Merck (MRK), is developing a protease inhibitor of its own. We think telaprevir’s slightly superior efficacy and convenience profile should give it an advantage with prescribers. However, Vertex has no commercialization experience, and Merck’s established salesforce and ability to package the drug with the current standard of care should help even the commercialization playing field. Vertex ranked number 1 on our 2010 biotech takeout list, and we continue to believe the firm would benefit from the sales know-how of a larger pharma player like current partner Johnson & Johnson (JNJ). The stock currently trades at a 25% discount to our fair value estimate, providing an attractive entry point for investors with a stomach for risk.

While Vertex also has a late-stage cystic fibrosis candidate and compounds in earlier-stage development, telaprevir remains the focus of investor excitement and the primary value driver of the firm. We give the drug a 70% chance of approval, 10% higher than our average Phase III drug. If telaprevir succeeds in clinching approval, our fair value estimate would rise to at least $50 (not including a takeout premium). With a drug on the market, we think Vertex could see profitability by 2013. However, a great deal is still unknown about telaprevir’s remaining late-stage data and commercialization plans. If telaprevir takes longer than expected or requires more resources to get to market, our fair value estimate would fall to under $30.

Human Genome’s Benlysta Could Break 50-Year Dearth of New Lupus Drugs

Human Genome Sciences’ (HGSI) lupus drug Benlysta could become the first lupus medication to gain approval in over five decades. The first-in-class drug has demonstrated promising Phase III data in seropositive patients–those with an autoantibody present in their bloodstream. While the drug has had issues demonstrating significant long-term efficacy, we think Benlysta could be a unique candidate to use in combination with the standard of care. With no direct treatment for lupus, any improvement to the current steroid-based treatment could make the drug very attractive, and we think Benlysta could turn into a blockbuster drug for the firm. Human Genome received a favorable advisory panel vote for Benlysta last month, with members voting 13 to 2 in favor of recommending approval and 14 to 1 that the drug’s safety profile was sufficient for approval. While the FDA has recently delayed its target decision date to March 10, 2011, we think the drug could still launch by mid-2011.

Human Genome has a robust pipeline and many drugs in clinical trials. If one product fails, the firm has other development options. However, much of the firm’s long-term value remains tied to Benlysta. If the firm’s share of Benlysta sales could surpass $1.5 billion by 2019, we would raise our fair value estimate to $27 per share. If Benlysta does not gain approval, Human Genome would be left to rely on earlier-stage pipeline candidates and two Phase III candidates that we believe have only modest commercial potential. Our fair value estimate in this case would fall to $5 per share. While we think the firm is fairly valued at current trading levels, Human Genome represents another key takeout opportunity, in our opinion. The company ranked number 3 on our 2010 list of biotech takeout targets, and we think an acquisitor like current partner GlaxoSmithKline (GSK) would make strategic sense.

MannKind’s Inhaled Insulin Faces High Hurdles

MannKind (MNKD) is developing Afrezza as an ultra-rapid-acting inhaled insulin therapy for patients with diabetes. In addition to allowing patients to forego the needle, Afrezza’s molecular structure may allow for superior disease management to injectable insulin. In trials, Afrezza achieved comparable levels of overall glucose control while also demonstrating a lower risk of hypoglycemia and weight gain than currently available products. Despite these advantages, MannKind received a complete response letter from the FDA asking for more data earlier this year. The good news for MannKind was that the FDA did not require additional Phase III trials, which likely would have been prohibitive for the unprofitable biotech.

MannKind expects to hear back from the FDA by Dec. 29, and we think there is a good chance Afrezza will be approved (we assign Afrezza an 85% chance of approval based on strong efficacy data and a clean safety record thus far). However, MannKind will face an uphill battle in its attempt to turn the product into a commercial hit. Afrezza’s predecessor in the inhaled insulin class, Pfizer (PFE) and Nektar’s (NKTR) Exubera, was removed from the market in 2007 after generating disappointing sales and being linked to a potential risk of lung cancer in former smokers. Although Afrezza’s clinical trials have yet to produce any red flags, we think Exubera’s failings will haunt MannKind’s efforts to win favor among prescribers. MannKind also trades at a discount to our fair value estimate, but we think Afrezza’s fate represents more of a binary outcome for the firm, unlike Vertex’s telaprevir or Human Genome’s Benlysta. The firm carries a very high uncertainty rating and should be regarded as a speculative investment.

Written by Lauren Migliore

Wall Street Breakfast: Must-Know News

  • Rio advances on Riversdale. Rio Tinto (RIO) moved forward with an A$3.9B ($3.9B) offer for Australian coking coal developer Riversdale Mining, after its earlier A$3.5B bid was rebuffed. Analysts said the move makes strategic sense for Rio, whose portfolio was underweight coking coal. The A$16/share offer was recommended by all of Riversdale’s board, except for the director appointed by major shareholder Tata Steel (TATLY.PK, but investors sent Riversdale shares up 1.6% in Aussie trading to A$16.57, suggesting they expect either a sweetened offer or a rival one. Premarket: RIO -1% (7:00 ET).
  • Rovi buys Sonic Solutions. Rovi Corp. (ROVI) will pay $720M in cash and stock to buy Sonic Solutions (SNIC), the owner of popular digital video player software DivX. The $14.17/share offer is a 26% premium to Sonic’s closing price yesterday. Rovi said the combined company will be better positioned to help movie studios sell content in the fast-growing digital entertainment market. The deal is expected to add $0.05-0.10 per share to Rovi’s adjusted earnings. Premarket: SNIC +24.7% to $13.97 (7:00 ET).
  • Advantest raises offer for Verigy. Advantest (ATE) has raised its takeover offer for Verigy (VRGY) by 23% to roughly $900M, equivalent to $15/share. Advantest had previously proposed to acquire Verigy for $12.15/share. Verigy’s board will consider the offer, but in the meantime its $600M merger deal with LTX-Credence (LTXC) remains in effect.
  • AIB poised for capital injection. Irish Finance Minister Brian Lenihan is expected to ask Ireland’s top court today for permission to inject €3.7B ($4.8B) of capital into troubled Allied Irish Bank (AIB). The move would leave the Irish government with more than a 90% stake in the lender, up from its current 19% stake. AIB is expected to acquiesce to the request, which would allow the injection to occur immediately, and the court’s involvement would allow the bank and the government to completely sidestep shareholders. Following the capital injection, the government may de-list AIB’s shares, despite earlier speculation that the stock would continue trading for at least the near future. Premarket: AIB -15.6% to $0.92 (7:00 ET).
  • Hilton settles Starwood suit. Hilton Worldwide reached an agreement to settle a corporate-espionage lawsuit filed last year by Starwood Hotels (HOT). Hilton officials had been accused of stealing confidential Starwood documents in order to build a modern boutique-style chain. As part of the settlement, Hilton agreed to never develop its Denizen lifestyle brand and can’t start developing a similar brand for two years. Hilton must also make an unspecified payment to Starwood, and must let a court-appointed monitor review its marketing material to ensure Hilton doesn’t benefit from material in the Starwood documents.
  • Barnes & Noble shareholder cuts stake. Money manager Aletheia Research and Management, the third largest shareholder of Barnes & Noble (BKS), has cut its stake in the struggling bookstore chain. According to regulatory filings, Aletheia now owns 7.67M Barnes & Noble shares, or a 12.7% stake, down from 14% last month and 15.1% earlier in the year.
  • Comcast-NBCU deal review extended to January. Comcast (CMCSA) confirmed yesterday that the regulatory review of its proposed NBC Universal (GE) deal will continue into January, stymying the company’s plans to close the controversial deal by the end of 2010. There had been ongoing rumors that regulatory approval would be delayed, but until yesterday both parties in the transaction had stood firm on their original timeline.
  • AstraZeneca, Abbott part ways on Certriad. AstraZeneca (AZN) ended its license agreement with Abbott Laboratories (ABT) to develop Certriad, a drug meant to treat mixed dyslipidemia. The mutual decision was prompted by an FDA decision in March 2010 which caused a regulatory delay in the drug’s commercialization, and the two firms jointly determined that their licensing agreement was “no longer commercially attractive.”
  • U.S. files WTO complaint against China. The Obama administration filed a complaint with the WTO over subsidies China provides its wind-energy manufacturers, acting on a petition brought by the United Steelworkers union. The U.S. claims that the Chinese government fund which awards grants to wind power manufacturers appears to require recipients to use Chinese-made parts, which violates WTO rules.

Earnings: Wednesday After Close

  • Bed Bath & Beyond (BBBY): Q3 EPS of $0.74 beats by $0.08. Revenue of $2.2B (+11.1%) vs. $2.1B. Shares +6.6% AH. Micron Technology (MU): FQ1 EPS of $0.15 misses by $0.13. Revenue of $2.3B (+32%) vs. $2.4B. Shares -3.6% AH. Today’s Markets
  • In Asia, Japan -0.2% to 10346. Hong Kong -0.6% to 22903. China -0.8% to 2855. India -0.2% to 19983.
  • In Europe, at midday, London +0.1%. Paris -0.4%. Frankfurt +0.1%.
  • Futures at 7:00: Dow flat. S&P -0.1%. Nasdaq -0.2%. Crude +0.1% to $90.61. Gold -0.3% to $1383.60.

Thursday’s Economic Calendar

8:30 Durable Goods
8:30 Personal Income and Outlays
8:30 Initial Jobless Claims
9:55 Reuters/UofM Consumer Sentiment
10:00 New Home Sales
10:30 EIA Natural Gas Inventory
10:30 ECRI Leading Index
4:30 PM Money Supply
4:30 PM Fed Balance Sheet

Written by Rachael Granby, SeekingAlpha
Original post

Lotus Pharmaceuticals (LTUS): The Big Little Chinese Drug Manufacturer

While speculative opportunities in small cap biotech continue to entertain investors, half-way across the world big little drug manufacturer, Lotus Pharmaceuticals, Inc. (OTCBB: LTUS), is operating to the tune of explosive growth – and out of its own pocket, too.
 
In addition to manufacturing their own branded drugs and pharmaceuticals products, Lotus Pharmaceuticals distributes over 5000 western drugs, Traditional Chinese Medicines (TCMs) and medical equipment items through wholesale and retail channels such as ten of their owned and operated pharmacies in Beijing.  
 
For the first three quarters of 2010, revenues totaled $52.5M or 31% higher than the comparable period in 2009. Wholesale revenue saw 18% growth while retail sales growth, at 83%, was the driving force behind top-line growth. This falls in line with the company’s recent announcement to forgo construction of a new facility outside of China and instead focus more on core business in Beijing.

“We have decided not to move forward with the construction of our planned facility in Inner Mongolia in order to focus our efforts and resources on expanding our core business in Beijing. We believe that selling or transferring this property will be a more effective use of our capital.”

 

In December of 2008 the company had acquired the property in Chahaer Industrial Park, Inner Mongolia for $26.3M. 
 
Assuming the property is sold on a timely schedule and at or near cost, proceeds from the sale will in part, if not wholly, finance growth and expansion plans in the upcoming period. Cash inflows from operating activities, which brought in $19M in the first three quarters of 2010, have helped balance outflows in investing activities. As a growing entity it is expected that the company will continue to invest in property and equipment. The beauty of the situation lies in that in case of a draught, the company always has the option of turning to shareholders or a low interest bank loan for quick access to capital resources.
 
Based on diluted EPS of $0.39, Lotus Pharmaceuticals currently trades at a trailing P/E ratio of 3.07. In contrast, companies in the healthcare sector boast double-digit P/E ratios. And while, in general, the recent fright over legitimacy of small-cap Chinese companies may continue to daunt investors, there are reasons beyond the scope of growth that deem Lotus Pharmaceuticals undervalued at its current price.
 
For instance, the market hasn’t taken into consideration Lotus Pharmaceuticals’ pipeline of drugs awaiting approval from China’s State Food and Drug Administration (SFDA).
 
 
 
Laevo-Bambutero, Lotus’ asthma drug, is anticipating SFDA approval by 2012. While that seems like light-years away it’s this type of inherent value that attracts large industry players to hostile takeovers.
 
Elsewhere, most recently being the PHARMCHINA 64th National Drug Fair Conference, the company continues to build its list of product distributors, which now totals 200. In the CEO’s own words, “Our participation in the PHARMCHINA conference was very fruitful, as we came away with six new contracts upstream and five downstream. We believe we are well-positioned to reach our goal of 25% top-line growth in 2011.”
 
And whether you like it or not, Lotus’ management is taking strides towards qualifying for a higher-exchange listing. More on this another time. 

Ireland Races to Secure Weekend Aid Deal Amid Bank Concern

Ireland is in the final stages of negotiating an international aid package to rescue its financial system before markets open on Monday after investors yesterday dumped the bonds of its largest banks.

Euro-area finance ministers may seal an agreement with Ireland tomorrow, with a teleconference slated to begin at 4 p.m. Brussels time, a European Union official said on condition of anonymity. The loans may cost as much as 6.7 percent, compared with a rate of 5.2 percent paid by Greece, state broadcaster RTE said, without citing anyone.

The need for a pact, which may be worth 85 billion euros ($112 billion), is intensifying as capital flows out of the nation’s banks. The Irish government two years ago assured senior bondholders they wouldn’t lose their money if banks failed. For negotiators, the risk is that breaking the pledge may spark concerns about the quality of other euro-region debt.

“One possible scenario is that the financial package for Ireland could include an element of restructuring affecting senior debt,” Fitch Ratings said in a statement yesterday. “Fitch has no visibility of this matter but notes that such a restructuring could have wider implications for the euro area.”

Allied Irish Banks Plc and Bank of Ireland Plc bonds fell yesterday on concern the government will abandon a pledge to protect senior bondholders and instead force them to share the bailout costs. EU and International Monetary Fund officials are taking legal advice on how senior bondholders can share the cost of the rescue without triggering lawsuits, the Irish Times said yesterday, without saying where it got the information.

Irish Crisis

Ireland’s crisis is now forcing Portuguese and Spanish politicians to quell speculation that they are next in line for rescue. The cost of insuring Portuguese, Irish and Spanish government debt against default yesterday rose to records based on closing prices, according to CMA.

“The sovereign debt crisis has gone from third to fifth gear in just a matter of days,” said Kathleen Brooks, research director at Gain Capital Group LLC in London. “Whereas the Greek crisis and the start of the Irish crisis were concerned with individual sovereigns and their problems, the current chapter of Europe’s sovereign woes has turned into a periphery- wide issue where no one is safe.”

Ireland may pay an average 6.7 percent for the loans, which would last nine years, RTE said. The cash will come from the European Commission, the IMF and the European Financial Stability Facility, which will charge different rates, RTE said. The IMF’s loans may be the cheapest at 4.5 percent, and the EFSF would be the most expensive, RTE said. The EFSF will provide the bulk of the overall bailout.

Hardball

Ireland’s debt agency has paid an average of 4.5 percent on funds raised over the past two years, RTE said.

“If that is true, it is too high,” Leo Varadkar, a spokesman for the opposition Fine Gael party, said on RTE. “The government in my view needs to play hardball.”

Allied Irish’s 750 million euros of 5.625 percent senior notes due 2014 plunged 2 cents on the euro to 75 cents, a 2.6 percent decline, according to composite prices on Bloomberg. Bank of Ireland’s 974 million euros of 4.625 percent senior unsecured notes maturing in 2013 fell 3 cents on the euro, or 3.4 percent, to 82 cents.

‘Similar Problems’

While deposit outflows have “stabilized” in recent weeks, Anglo Irish Bank Corp. Chairman Alan Dukes told Bloomberg Television two days ago that the nationalized lender lost about 12 billion euros of deposits this year and that “other banks are having similar problems.” Anglo Irish yesterday had its long-term counterparty credit rating cut to below investment grade by Standard & Poor’s, which cited concerns about sovereign support for the bank.

Deposits at Allied Irish and Bank of Ireland have fallen by a combined 22 billion euros since the end of June, according to estimates from Emer Lang, an analyst at Dublin-based securities firm Davy.

Governments elsewhere in Europe pushed back against investor bets they may next be in line for a bailout. The average yield investors demand to hold 10-year debt from Greece, Ireland, Portugal, Spain and Italy yesterday reached a euro-area record of 7.57 percent. By contrast, Germany pays 2.73 percent.

Portugal’s government denied a report in the Financial Times Deutschland that it’s being forced to seek aid. The country’s parliament yesterday approved the government’s 2011 budget proposals, which include the deepest spending cuts in more than three decades. The European Central Bank bought the country’s bonds yesterday, according to people familiar with the transactions.

‘Wrong’

European Commission President Jose Barroso said in Paris yesterday that “it’s completely wrong” to suggest the commission has lobbied Portugal. The German government “isn’t pressing anybody to seek funding,” Steffen Seibert, Chancellor Angela Merkel’s chief spokesman, told reporters in Berlin.

“There are those who think that the best way to preserve the stability of the euro is to push and force the countries that at this moment have been more under the floodlight to that aid,” Portuguese Finance Minister Fernando Teixeira dos Santos told Jornal de Noticias in an interview published yesterday. “But that is not the vision or the political option of the countries that are involved.”

Spanish Prime Minister Jose Luis Zapatero told Catalan radio RAC1 that investors who are “short” on Spain “are going to be wrong and will go against their own interests.” Finance Minister Elena Salgado said that Spain will issue less debt at the remaining auctions of 2010 because the nation’s financing needs for this year are already covered.

Irish Woes

Ireland’s woes are having domestic political repercussions. Prime Minister Brian Cowen’s party lost a special election for a vacant parliamentary seat to a Sinn Fein candidate who said he wanted to “burn” holders of bank debt. The premier probably will still be able to pass the 2011 budget even though the loss reduces his parliamentary majority to two.

While opposition political parties back the aim of reducing the budget deficit to the EU’s 3 percent limit by 2014, labor unions are planning a “mass mobilization” in protest at the planned cuts, with a march in Dublin today.

 

Written by Dara Doyle and Simon Kennedy

Casinos struggle back from recession

Amid a new reality — casinos are not recession-proof — gambling in Louisiana and Mississippi is staging a slow comeback from the economic meltdown of 2008, aggravated for a time by the Gulf of Mexico oil spill that chased away some tourists.

But at least for the rest of 2010 and into 2011, industry analysts expect many players to keep a tight grip on their wallets amid uncertain economic times — and those who watch casinos are largely unwilling to predict when full recovery might come.

“Gamblers, like other people, have to feel comfortable about their financial situation,” said Joseph Weinert, senior vice president of Linwood, N.J.-based Spectrum Gaming Group. “There had been the perception that the industry was largely recession-proof, but we saw what happened a couple of years ago. When the economy got tanked, the industry got whacked.”

For the first three quarters of 2010, revenue at Mississippi’s state-licensed casinos totaled $1.83 billion, down 12.9 percent from the first nine months of 2008 — the period leading into the U.S. economic freefall. Still, the decline has slowed. According to the Mississippi Department of Revenue, casino takes dropped only 3.3 percent from the first three quarters of 2009.

In the latest count, the 11 casinos across the Mississippi Gulf Coast were down 12.7 percent from the first nine months of 2008, but recorded only a 1.3 percent drop from 2009, indicating that the oil spill had only a small effect on gambling. The 19 casinos on the Mississippi River, including Tunica in the Arkansas-Tennessee corner, were down 12.8 percent from 2008 and 5 percent from last year.

In Louisiana, the 13 riverboat casinos, Harrah’s downtown New Orleans casino and the four race track casinos, for the first three quarters of 2010, recorded a 7.7 percent drop in gambling revenue from the first nine months of 2008. The 2010 tally was down 5.3 percent from 2009.

“I’m reserved, but optimistically reserved. The numbers appear to be stabilizing,” said Dane Morgan, chairman of the Louisiana Gaming Control Board.

But sustained growth is a question mark, regionally and nationally.

Recently, at the Global Gaming Expo in Las Vegas, American Gaming Association head Frank Fahrenkopf said gambling revenue in state-licensed casinos rose 1.3 percent — or to just over $8 billion — from the second quarter to the third quarter of 2010. But that’s still about $100 million less than casinos took in during the same period last year. Fahrenkopf blamed that on reduced discretionary spending by consumers.

Earlier this month, Jefferies & Co. analyst David Katz said he expected Louisiana and Mississippi casinos owned by Penn National Gaming Inc., Pinnacle Entertainment Inc., Boyd Gaming Corp. and MGM Resorts International to report mixed results during fourth-quarter revenue reports, saying the region’s recovery still lags behind other markets.

“Right now, the gaming industry is largely a function of the regional and national economies,” Weinert said. “It depends upon whether you see those economies flatten out or start showing some life. The casinos will follow that.”

A large chunk of Louisiana’s casino business is pointed at Texans. Shreveport-Bossier City gambling revenue, for the first three quarters of 2010, fell 10.5 percent from the first nine months of 2008. The recent tally is down 4.4 percent from 2009. The five riverboats and the track casino in that market have been facing increased competition from Indian nation casinos in Oklahoma.

In Lake Charles, where direct competition is more isolated for three riverboats and a track casino, the tally is just about the same in comparing 2008 and 2010, although down 5.8 percent from 2009. The 2008 figures were skewed by September when two major hurricanes chopped at as much as $20 million from the historic monthly count.

In the New Orleans area, which has two riverboats and a track casino along with the land casino, gambling revenue is down 9.4 percent in the three-quarter comparison of 2008 to 2010 and down 2.9 percent from 2009. The boats and the track casino generally appeal to a local market, while Harrah’s — more aimed toward tourists and the convention business — typically posts big months during such events as Mardi Gras, the New Orleans Jazz & Heritage Festival, the Essence Festival and big-ticket sporting events.

But more outlets want to get into the competitive fray, despite the slower times. Pinnacle hopes to open its $357 million riverboat casino-hotel project in Baton Rouge in December 2011. That market, which currently has two gambling boats, has seen a 13.3 percent drop in revenue from the first three quarters of 2008 to the first three of 2010.

“I think a new casino will grow that market, but it will be at the expense of the other operators,” said industry analyst Cory Morowitz of Galloway, N.J.-based Morowitz Gaming Advisors. “There’s not enough room otherwise.”

Three groups have filed for the 15th and final riverboat license allowed by Louisiana law. Two want another Lake Charles casino, while the other wants another suburban New Orleans boat.

Louisiana regulator Morgan said he hopes a decision on the winner will be made by March.

In Mississippi, Gaming Commission executive director Larry Gregory said no new projects are near fruition, but investors continue to express interest in the state, especially along the coast.

“We have had a lot of interest over the past year. People coming down here and looking and wanting to move forward with something. But in today’s economy, it’s difficult to fund these projects,” Gregory said. “The coast is prime for development. But it’s not just us. You look at mature jurisdictions all over, not new ones, there are just not many projects.”

Written by Alan Sayre